PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024

February 7, 2024
Language flag

Phase Holographic Imaging (PHI) announces its participation in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024. This event offers a valuable platform for PHI to connect with fellow companies in the field and present the Company’s innovative offerings for regenerative medicine and cell therapy.

PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024.

As a pioneering force in medical technology, PHI specializes in developing advanced microscope-based research instruments that revolutionize the study of living cell cultures. PHI’s non-invasive cell imaging and analysis method is considered one of the very few methods that have the potential to become standards for the quality, safety and democratization of future cell therapies.

PHI’s CEO, Patrik Eschricht, will showcase the company’s latest advancements and detail how the company is uniquely positioned to contribute to the rapidly growing field of regenerative medicine and cell therapy research.

Date: February 14, 2024
Time: 09.10 AM
Watch live: https://www.redeye.se/events/966283/redeye-theme-cell-therapy

Subscribe to PHI news on cision.com

Latest News

Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 14 March 2024

On Thursday, March 14, 2024, Phase Holographic Imaging PHI AB (publ), held an extraordinary general meeting. The following resolutions were passed at the meeting.
blue-cells_white-bg_banner

Shaping the future of Regenerative Medicine – PHI’s vision for QPI in Cell Therapy Manufacturing

PHI presents a comprehensive opinion piece detailing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.
Altium_logo

New Distributor Partner Manager at Altium set to enhance global sales for PHI

PHI is conveying the news that its global distributor, Altium ., has appointed a PHI-dedicated distributor partner manager. This strategic step is set to significantly enhance the reach and sales performance of PHI’s HoloMonitor technology on a global scale.
See All News